Peptide Initiative

Peptides · Peptide comparison

Cerluten vs Cortexin

Brain-derived peptide bioregulator complex containing AED, KED, AEDG, and KE peptides that promote neurogenesis through histone binding, restore dendritic spine architecture under neurotoxic conditions, and enhance cognitive recovery in stroke and brain injury patients

Bovine cerebral cortex-derived polypeptide preparation with nootropic, neuroprotective, and antioxidant properties used clinically in Russia for cerebrovascular disorders, cognitive impairment, and pediatric neurology

  • Cognitive
  • Cognitive

At a glance

Quick comparison

Dose rangeCerluten1–2 capsulesCortexin10–10 mg
FrequencyCerlutenOnce dailyCortexinOnce daily
AdministrationCerlutenOral (capsule)CortexinIntramuscular (IM) injection
Cycle lengthCerluten8-12 weeksCortexin8-12 weeks
Onset speedCerlutenGradual (3-4 weeks)CortexinModerate (1-2 weeks)
Evidence levelCerlutenLimited human trialsCortexinLimited human trials

Efficacy

Benefit ratings

Neuroprotection

Cerluten62%
Cortexin88%

Post-Stroke Recovery

Cerluten58%
CortexinNo recorded rating

Brain Cell Renewal

Cerluten45%
CortexinNo recorded rating

Brain Recovery

CerlutenNo recorded rating
Cortexin94%

Cognitive Function

CerlutenNo recorded rating
Cortexin91%

Technical data

Compound specifications

Cerluten

Molecular formula
C11H17N3O8 (representative primary component)
Molecular weight
319.3 g/mol (representative; complex contains peptides from 200-500 Da)
Half-life
Short plasma half-life for individual peptide components (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to gene expression
Bioavailability
Oral and sublingual absorption via intestinal peptide transporters (PepT1); component peptides cross the blood-brain barrier; sublingual form bypasses first-pass hepatic metabolism
CAS number
75007-24-8

Cortexin

Molecular formula
Complex mixture — no single molecular formula (contains multiple low molecular weight polypeptide fractions, L-amino acids, vitamins, and trace elements)
Molecular weight
Low molecular weight water-soluble polypeptide fractions — specific molecular weight distribution varies as a complex biological mixture
Half-life
Approximately 2-6 hours (varies by route of administration)
Bioavailability
~85-100% (intramuscular injection)
CAS number
Not assigned (biological mixture)

Protocols

Dosing compared

Cerluten

Oral

  • 1-2 capsules (0.2 g each)1-2 times daily with meals · 30-day intensive course; then 10-day maintenance course every 3 monthsThe common capsule plan used in practice for this CNS peptide supplement. A typical intensive start is 2 capsules daily for 30 days, then 2 capsules daily for 10 days every 3 months. [6]

Sublingual

  • 5-6 drops3-4 times daily under the tongue · 10-30 day course, repeated 2-3 times per yearThe liquid form is held under the tongue so it absorbs directly. Commonly used at 5-6 drops several times a day. [6]

Cortexin

Intramuscular

  • 10 mgOnce daily · 10 days per course; repeat in 3-6 months if neededThe standard adult dose per the manufacturer instructions. The 10 mg vial is dissolved in 1-2 mL of saline, water for injection, or 0.5% procaine and injected into a muscle. Children under 20 kg get 0.5 mg/kg. [6]

Applications

Best suited for

Cerluten

Cognitive recovery following stroke or traumatic brain injury
Cerluten is particularly well-suited for individuals focused on cognitive recovery following stroke or traumatic brain injury. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Neuroprotection against age-related cognitive decline and neurodegeneration
Cerluten is particularly well-suited for individuals focused on neuroprotection against age-related cognitive decline and neurodegeneration. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting neurogenesis and neuronal repair in aging brain tissue
Cerluten is particularly well-suited for individuals focused on supporting neurogenesis and neuronal repair in aging brain tissue. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive bioregulatory approach to brain aging using multiple complementary peptide components
Cerluten is particularly well-suited for individuals focused on comprehensive bioregulatory approach to brain aging using multiple complementary peptide components. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Cortexin

Cognitive support in chronic cerebral ischemia and cerebrovascular disease
Cortexin is particularly well-suited for individuals focused on cognitive support in chronic cerebral ischemia and cerebrovascular disease. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
Neuroprotection and neurorecovery following stroke or traumatic brain injury
Cortexin is particularly well-suited for individuals focused on neuroprotection and neurorecovery following stroke or traumatic brain injury. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [7].
Pediatric neurology including cerebral palsy and developmental delays
Cortexin is particularly well-suited for individuals focused on pediatric neurology including cerebral palsy and developmental delays. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [7][8].
Adjunctive treatment in epilepsy management
Cortexin is particularly well-suited for individuals focused on adjunctive treatment in epilepsy management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [7][8].

Safety profile

Side effects

Cerluten

Common

  • Mild headache
  • Mild drowsiness
  • Mild GI discomfort
  • Vivid dreams

Uncommon

  • Transient sleep pattern changes

Serious

  • No documented serious adverse effects

Cortexin

Common

  • Injection site reactions
  • Headache
  • Dizziness
  • Nausea
  • Agitation or restlessness
  • Transient blood pressure changes

Uncommon

  • Allergic reactions

Serious

  • Severe allergic reaction / Anaphylaxis

Research status

Safety & evidence

Cerluten

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Cerluten is a peptide extract from cerebral tissue of young animals that is not FDA-approved and lacks rigorous clinical safety data. As an undefined mixture of peptides and proteins from animal sources, quality control and batch consistency cannot be guaranteed. Potential risks include allergic reactions to animal-derived proteins, contamination with microbial pathogens or prions, and unknown long-term immunological effects. No comprehensive safety studies have been conducted in humans, and the active pharmaceutical components have never been identified or standardized. The product exists primarily in Russian and Eastern European medical markets without Western regulatory oversight.

Contraindications

  • Known hypersensitivity to peptide bioregulators or bovine-derived products
  • Pregnancy and breastfeeding — insufficient reproductive safety data
  • Active CNS infection — treat infection before initiating peptide bioregulator therapy
  • Prion disease concerns — although manufacturing processes include purification to remove proteins > 5 kDa, individuals with heightened prion risk should exercise caution

Cortexin

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Cortexin is a porcine brain-derived polypeptide preparation used in Russian neurology that is not FDA-approved and has no Western rigorous safety data. As an undefined mixture of peptides and proteins extracted from animal brains, batch standardization and quality control are not guaranteed. Concerns include potential transmissible spongiform encephalopathy (TSE/prion) risk from animal CNS tissue, although documented cases have not been reported. Allergic reactions to porcine proteins are possible. No formal human safety assessments, toxicology studies, or clinical trials by modern regulatory standards have been conducted. Use in Western countries is essentially non-existent due to regulatory limitations on animal-derived neurological products.

Contraindications

  • Known hypersensitivity to Cortexin or any component including glycine stabilizer
  • Allergy to bovine-derived biological products
  • Pregnancy — insufficient safety data for use during pregnancy
  • Breastfeeding — insufficient data on excretion into breast milk

Decision guide

Which is right for you?

Cerluten

Choose Cerluten if…

  • Cognitive recovery following stroke or traumatic brain injury
  • Neuroprotection against age-related cognitive decline and neurodegeneration
  • Supporting neurogenesis and neuronal repair in aging brain tissue
  • Comprehensive bioregulatory approach to brain aging using multiple complementary peptide components

Cortexin

Choose Cortexin if…

  • Cognitive support in chronic cerebral ischemia and cerebrovascular disease
  • Neuroprotection and neurorecovery following stroke or traumatic brain injury
  • Pediatric neurology including cerebral palsy and developmental delays
  • Adjunctive treatment in epilepsy management